MINOTENSOL 7.5 MG 20 F.C.TAB

INDICATION FOR THE TREATMENT OF HYPERTENSION. MECHANISM OF ACTION MOEXIPRIL IS A PRODRUG FOR MOEXIPRILAT WHICH INHIBITS ACE IN HUMANS AND ANIMALS. THE MECHANISM THROUGH WHICH MOEXIPRILAT LOWERS BLOOD PRESSURE IS BELIEVED TO BE PRIMARILY INHIBITION OF ACE ACTIVITY. ACE IS A PEPTIDYL DIPEPTIDASE THAT CATALYZES THE CONVERSION OF THE INACTIVE DECAPEPTIDE ANGIOTENSIN I TO THE VASOCONSTRICTOR SUBSTANCE ANGIOTENSIN II. ANGIOTENSIN II IS A POTENT PERIPHERAL VASOCONSTRICTOR THAT ALSO STIMULATES ALDOSTERONE SECRETION BY THE ADRENAL CORTEX AND PROVIDES NEGATIVE FEEDBACK ON RENIN SECRETION. ACE IS IDENTICAL TO KININASE II AN ENZYME THAT DEGRADES BRADYKININ AN ENDOTHELIUM-DEPENDENT VASODILATOR. MOEXIPRILAT IS ABOUT 1000 TIMES AS POTENT AS MOEXIPRIL IN INHIBITING ACE AND KININASE II. INHIBITION OF ACE RESULTS IN DECREASED ANGIOTENSIN II FORMATION LEADING TO DECREASED VASOCONSTRICTION INCREASED PLASMA RENIN ACTIVITY AND DECREASED ALDOSTERONE SECRETION.